Clinical trial · Observational
The Relationship Between The Differential Expression Of FosB Protein In Laryngeal Cancer Tissues And Clinical Prognosis
Expression Of FosB Gene In Laryngeal Cancer Tissues And It's Clinical Prognosis Significance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine whether there is statisstical difference in FosB (FBJ murine osteosarcoma viral oncogene homolog B) protein expression between laryngeal cancer tissue and adjacent tissue through immunohistochemistry methods. If there are differences, further the investigators will collect relevant patients information,such as clinical stages, pathological types, clinical prognosis and so on. ultimately analyze whether it is related to the expression of FOsB in laryngeal cancer tissue and adjacent tissues
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Laryngeal Carcinoma | Laryngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| the expression negative in laryngeal cancer tissue | Other | — | UNRESOLVED |
| the expression positive in laryngeal cancer tissue | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- The expression of FosB positive group
- description
- Researcher will incorporate the positive expression of FosB protein in laryngeal cancer tissues into the positive study group by immunohistochemical methods!
- interventionNames
- Other: the expression positive in laryngeal cancer tissue
- label
- The expression of FosB negative group
- description
- Researcher will incorporate the positive expression of FOSB protein in laryngeal cancer tissues into the positive study group and vice versa into the negative study group by immunohistochemical methods!
- interventionNames
- Other: the expression negative in laryngeal cancer tissue
Primary outcomes (1)
- measure
- the number of fosb gene positive expression cases in laryngeal carcinoma cells and adjacent tissues was determined.
- timeFrame
- one month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * laryngeal squamous cell carcinoma was diagnosed ,and biopsy was confirmed by two pathologists; * Primary tumor of Laryngeal ,and there was no distant metastasis; * Standard treatment such as surgery and Preliminarily-diagnosed parients; * full clinical and pathological data information and good follow-up; * there was no previous fatal diseases such as complicated tumors. Exclusion Criteria: * Secondary cancer or cancer with distant metastasis; * Patients who have not seen a doctor for the first time or have received surgery or radiotherapy or chemotherapy in other hospitals; * Clinical and pathological data were missing and loss to follow-up; * Patients who abandoned treatment or standard treatment procedures has not been completed; * The past medical history of other lethal diseases such as complicated tumors.
References
Publications (3)
- BACKGROUNDLiu S, Luan J, Ding Y. miR-144-3p Targets FosB Proto-oncogene, AP-1 Transcription Factor Subunit (FOSB) to Suppress Proliferation, Migration, and Invasion of PANC-1 Pancreatic Cancer Cells. Oncol Res. 2018 Jun 11;26(5):683-690. doi: 10.3727/096504017X14982585511252. Epub 2017 Jun 24. PMID 28653602
- BACKGROUNDHung YP, Fletcher CD, Hornick JL. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma. Am J Surg Pathol. 2017 May;41(5):596-606. doi: 10.1097/PAS.0000000000000795. PMID 28009608
- RESULTEferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003 Nov;3(11):859-68. doi: 10.1038/nrc1209. No abstract available. PMID 14668816